	CIOMS FOR														RIVI		
SUSPECT ADVERSE REACTION REPORT																	
						I	_				_		_		_	_	
		I REA	CTION	INFOR	MATION	- _	•										
1. PATIENT INITIALS	1a. COUNTRY	2. DATE OF BIRTH	2a. AGE	3. SEX	3a. WEIGHT	1	REA	CTION	ONSE	ΞT	8-12		ECK.				
(first, last) PRIVACY	GUATEMALA	Day Month Year PRIVACY	Unk	Female	Unk	Day		Month Unk	\	Year	APPROPRIATE TO ADVERSE REACTION						
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)											PATIENT DIED						
the medication does not come out of the needle [Device delivery system no flow] problem with the device, on Saturday we could no longer inject my daughter [Drug dose omission by device]										INVOLVED OR PROLONGED INPATIENT HOSPITALISATION							
Case Description: This is a spontaneous report received from a Consumer or other non HCP from product quality group, Program ID: 164974.										INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY							
A female patient (unknown if pregnant) received somatropin (GENOTROPIN PEN), (Batch/Lot number:																	
unknown). (Continued on Additional Information Page									age)	LIFE THREATENING							
	II. SUSPECT DRUG(S) INFORMATION																
14. SUSPECT DRUG(S) (include generic name) #1) Genotropin Pen (SOMATROPIN) Solution for injection #2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection											20. DID REACTION ABATE AFTER STOPPING DRUG?						
#1) UNK					ROUTE(S) OF ADMINISTRATION) Unknown) Unknown							YES NO NA					
17. INDICATION(S) FOR USE											ID REA			R			
#1) Unknown #2) Unknown												REINTR					
1					THERAPY DURATION) Unknown							YES NO NA					
#2) Unknown #2					2) Unknown												
		III. CONCOMIT			AND H	ISTO	R۱	′									
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)																	
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown																	
Grindrown.																	
_		IV. MANUF	ACTUR	ER INF	ORMAT	ION											
24a. NAME AND ADDRE Pfizer S.A.	26. REM																
Laura Arce Mora Avenida Escazú, T																	
San jose, COSTA																	
		24b. MFR CONTROL NO. PV202500059164				25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.											
24c. DATE RECEIVED BY MANUFACTURE	24d. REPORT																
28-MAY-2025	STUDY HEALTH PROFES	LITERATURE SSIONAL OTHER: Sponta	aneous														
DATE OF THIS REPORT 02-JUN-2025			1														

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: DEVICE DELIVERY SYSTEM ISSUE (non-serious), described as "the medication does not come out of the needle"; DRUG DOSE OMISSION BY DEVICE (non-serious), described as "problem with the device, on Saturday we could no longer inject my daughter". The action taken for somatropin was unknown.

Additional Information: Product Quality Group provided investigational results on 28May2025 for somatropin (device constituent): Investigation Summary and Conclusion: Site Investigation (Pfizer Manufacturing Site): No further investigation was required as no valid lot number or returned sample was available. This complaint will continue to be trended. If additional information becomes available, this complaint will be reopened. Device Investigation: This investigation is based on the information captured in the Complaint Description and Argus Report. The Complaint Issue, Injection Failure/Blocked, was reported. The Risk Management File was reviewed to confirm that the Hazard(s) and Hazardous Situation(s) associated with the Complaint Issue are documented in the Hazard Analysis (INX# INX100281795, Version # (9.0)). All complaint investigations are trended. There is no current trend alert documented.

Causality for "problem with the device, on saturday we could no longer inject my daughter" and "the medication does not come out of the needle" was determined associated to device constituent of somatropin (malfunction).

Follow-up (28May2025): This is a spontaneous follow-up report from product quality group providing investigation results.